Pages that link to "Q50583960"
Jump to navigation
Jump to search
The following pages link to Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. (Q50583960):
Displaying 50 items.
- Strategies to reduce hepatitis C virus recurrence after liver transplantation (Q22305418) (← links)
- Aminoadamantanes versus other antiviral drugs for chronic hepatitis C (Q24193940) (← links)
- Aminoadamantanes for chronic hepatitis C (Q24194770) (← links)
- Nitazoxanide for chronic hepatitis C (Q24197485) (← links)
- Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C (Q24200189) (← links)
- Era of direct acting antivirals in chronic hepatitis C: Who will benefit? (Q26777506) (← links)
- Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria (Q27329877) (← links)
- Therapeutic issues in HIV/HCV-coinfected patients (Q27481053) (← links)
- Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition (Q27490340) (← links)
- Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan (Q27490399) (← links)
- G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence (Q27490405) (← links)
- Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment (Q27490841) (← links)
- Diagnosis, management, and treatment of hepatitis C: an update (Q29619682) (← links)
- An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver (Q30453975) (← links)
- Hematologic disorders associated with hepatitis C virus infection and their management (Q33349378) (← links)
- Complementary treatments of chronic viral hepatitis C (Q33370676) (← links)
- Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis (Q33394544) (← links)
- Laparoscopic splenectomy with interferon therapy in 100 hepatitis‐C‐virus‐cirrhotic patients with hypersplenism and thrombocytopenia (Q33396388) (← links)
- Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin (Q33408043) (← links)
- Treatment outcome in chronic hepatitis C infection: a four years survey among Iranian patients (Q33422617) (← links)
- Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin (Q33639642) (← links)
- Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes (Q33988285) (← links)
- Treatment of hepatitis C virus infection (Q34099424) (← links)
- Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects (Q34164776) (← links)
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infection (Q34168383) (← links)
- Management of Hepatitis C Antiviral Therapy Adverse Effects (Q34538771) (← links)
- Antiviral Therapy in Patients after Treatment for Hepatitis C-Related Hepatocellular Carcinoma (Q34725891) (← links)
- The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients (Q34996746) (← links)
- Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection (Q35082620) (← links)
- Side effects of therapy for chronic hepatitis C. (Q35133495) (← links)
- Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens (Q35597625) (← links)
- Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C (Q35640461) (← links)
- Recent trends in the treatment of chronic hepatitis C (Q35890619) (← links)
- Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes (Q35944276) (← links)
- Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients (Q36327795) (← links)
- Hepatitis C virus infection in African Americans (Q36328945) (← links)
- Therapy of hepatitis C: from empiricism to eradication (Q36382235) (← links)
- Immunogenicity and acceptance of influenza A (H1N1) vaccine in a cohort of chronic hepatitis C patients receiving pegylated-interferon treatment (Q36384717) (← links)
- Treating viral hepatitis C: efficacy, side effects, and complications (Q36564615) (← links)
- Present and future therapy for hepatitis C virus (Q36670887) (← links)
- Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. (Q36735210) (← links)
- What the infectious disease physician needs to know about pegylated interferon and ribavirin (Q36811232) (← links)
- SASLT practice guidelines: management of hepatitis C virus infection. (Q37019765) (← links)
- Racial differences in hepatitis C treatment eligibility (Q37077462) (← links)
- In the clinic. Hepatitis C. (Q37180035) (← links)
- Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study (Q37669904) (← links)
- Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. (Q37851006) (← links)
- Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation (Q37892651) (← links)
- Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans (Q38087506) (← links)
- Side effects of cytokines approved for therapy (Q38255698) (← links)